Norgine Concludes Acquisition of Theravia

Norgine, an international specialty pharma and consumer healthcare company, has announced the successful acquisition of Theravia, a pharmaceutical firm that specializes in treatments for rare and serious diseases. This transaction, which positions Theravia as a wholly-owned subsidiary of Norgine, underscores the company's commitment to expanding its portfolio in areas with high unmet medical needs, particularly in Europe, Australia, and New Zealand. With a well-established integration process, Norgine plans to align operations, systems, and teams while expanding their expertise in rare diseases. Norgine, boasting a history of over 120 years and an annual revenue exceeding €550 million, aims to leverage Theravia's expertise to enhance its medical offerings. This acquisition is seen as a key step in Norgine's growth strategy to provide transformative medications to more patients.